Libivirumab: Difference between revisions
No edit summary |
m (Robot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
(One intermediate revision by the same user not shown) | |||
Line 27: | Line 27: | ||
{{SI}} | {{SI}} | ||
'''Libivirumab''' is a [[human]] [[monoclonal antibody]] which is used in the treatment of viral infections. | '''Libivirumab''' is a [[human]] [[monoclonal antibody]] which is used in the treatment of viral infections. |
Latest revision as of 16:52, 9 August 2012
WikiDoc Resources for Libivirumab |
Articles |
---|
Most recent articles on Libivirumab Most cited articles on Libivirumab |
Media |
Powerpoint slides on Libivirumab |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Libivirumab at Clinical Trials.gov Clinical Trials on Libivirumab at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Libivirumab
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Libivirumab Discussion groups on Libivirumab Patient Handouts on Libivirumab Directions to Hospitals Treating Libivirumab Risk calculators and risk factors for Libivirumab
|
Healthcare Provider Resources |
Causes & Risk Factors for Libivirumab |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Libivirumab is a human monoclonal antibody which is used in the treatment of viral infections.